全文获取类型
收费全文 | 314篇 |
免费 | 75篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 10篇 |
妇产科学 | 2篇 |
基础医学 | 28篇 |
口腔科学 | 5篇 |
临床医学 | 72篇 |
内科学 | 67篇 |
皮肤病学 | 17篇 |
神经病学 | 11篇 |
特种医学 | 84篇 |
外科学 | 30篇 |
综合类 | 5篇 |
现状与发展 | 1篇 |
预防医学 | 17篇 |
眼科学 | 2篇 |
药学 | 9篇 |
肿瘤学 | 34篇 |
出版年
2024年 | 4篇 |
2023年 | 24篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2020年 | 16篇 |
2019年 | 5篇 |
2018年 | 16篇 |
2017年 | 20篇 |
2016年 | 20篇 |
2015年 | 10篇 |
2014年 | 18篇 |
2013年 | 14篇 |
2012年 | 5篇 |
2011年 | 2篇 |
2010年 | 13篇 |
2009年 | 12篇 |
2008年 | 5篇 |
2007年 | 10篇 |
2006年 | 2篇 |
2005年 | 6篇 |
2004年 | 3篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 2篇 |
2000年 | 4篇 |
1999年 | 6篇 |
1998年 | 17篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 19篇 |
1993年 | 10篇 |
1992年 | 7篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 12篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1984年 | 11篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1975年 | 4篇 |
排序方式: 共有398条查询结果,搜索用时 15 毫秒
21.
Four patients with Philadelphia (Ph') positive chronic myeloid leukemia (CML) were studied before, after, and on relapse following allogeneic bone marrow transplantation (BMT). Southern analysis of DNA from cells collected before and at relapse after BMT was performed in order to investigate the origin of the leukemia at relapse. Using minisatellite probes we showed that the relapse occurred in cells of host origin in all four patients and this was confirmed with a Y chromosome specific probe in two male patients who had a female donor. Furthermore, using two probes for the breakpoint cluster region (bcr) on chromosome 22, we showed that leukemic cells at relapse bore identical rearrangements to those in the disease at time of presentation of each patient. We conclude that relapse in all four patients is due to re-emergence of the original leukemic clone. 相似文献
22.
Jin Zhang BD Xiao-Ying Hu BD Hong Ye BD Xiu-Qiu Fan BD Dong-Mei Lai BD 《Public health nursing (Boston, Mass.)》2023,40(1):97-104
Objective
To explore the clinical effect of the tuberculosis (TB) doctor–nurse integration management modelMethods
This study is a retrospective historical cohort study. The clinical data of 180 patients with TB in our hospital from 2019 to 2020 were analyzed retrospectively. In a control group, 90 cases were treated with the traditional medical care model. An observation group of 90 cases received clinical diagnoses, treatments, and nursing under a doctor–nurse integration management model. Comparative analyses between the two groups were conducted on various aspects, including the awareness level of TB prevention and control, medication compliance and patient satisfaction. Comparisons between the two groups were evaluated using independent-sample t-tests or Chi-squared testsResults
Compared with the control group, the knowledge awareness levels of TB prevention and medication compliance in the observation group were significantly higher (p < .05). The appointment waiting times and hospitalization times in the observation group were significantly lower than in the control group (p < .05). The total average satisfaction score of the patients in the observation group was significantly higher than in the control group (p < .05). Compared with the control group, the patients in the observation group were significantly more satisfied with their nursing methods, operating techniques, psychological techniques, service attitudes, and ward management (p < .05). In addition, in the observation group, medical–nursing relationships and doctor–patient communication were better than in the control group; additionally, the satisfaction of doctors with nursing work was also higher than in the control group, which was a statistically significant difference (p < .05)Conclusion
The implementation of an integrated medical–nursing cooperation model for TB will help increase the awareness of health knowledge in patients with TB, improve patient medication compliance and enhance patient satisfaction. 相似文献23.
24.
25.
Bo Wang MD Jue Wang BD Zhidong Cen MD Wei Wei MEd Fei Xie MD You Chen MD Haiyang Sun MD Yunsong Hu BD Dehao Yang MD Yuting Lou MD Xinhui Chen MD Zhiyuan Ouyang MD Si Chen MD Haotian Wang MD Lebo Wang MD Shuang Wang MD Xia Qiu MD Yao Ding MD Houmin Yin MD Sheng Wu MD Baorong Zhang MD Yu-Feng Zang MD Wei Luo MD PhD 《Movement disorders》2020,35(6):1012-1020
26.
BD Heckman KA Holroyd G Tietjen FJ O'Donnell L Himawan C Utley R Watakakosol & M Stillman 《Cephalalgia : an international journal of headache》2009,29(6):650-661
This study sought to determine if Whites and African-Americans respond similarly to headache treatment administered in 'real-world' headache specialty treatment clinics. Using a naturalistic, longitudinal design, 284 patients receiving treatment for headache disorders completed 30-day daily diaries that assessed headache frequency and severity at pretreatment and 6-month follow-up and also provided data on their headache disability and quality of life at pretreatment and 1-, 2- and 6-month follow-up. Controlling for socioeconomic status and psychiatric comorbidity, hierarchical linear models found that African-Americans and Whites reported significant reductions in headache frequency and disability and improvements in life quality over the 6-month treatment period. African-Americans, unlike Whites, also reported significant decreases in headache severity. Nevertheless, Africans-Americans had significantly more frequent and disabling headaches and lower quality of life after treatment relative to Whites. Although Whites and African Americans responded favourably to headache treatments, more efficacious treatments are needed given the elevated level of headache frequency that remained in both racial groups following treatment. 相似文献
27.
L. Zheng PhD Y.-p. Qing MD N. Xu MD Q. Yu BD Y. Wang BD F.-p. Wang† PhD Z.-y. Li‡ MD 《Journal of clinical pharmacy and therapeutics》2010,35(1):113-119
Objective: To investigate the safety and pharmacokinetics of bromotetrandrine (BrTet, W198), a novel inhibitor of P‐glycoprotein (P‐gp), after single‐dose i.v. infusion in healthy Chinese volunteers. Methods: We conducted a randomized, dose‐escalating, phase I clinical study for that purpose. Thirty healthy subjects received BrTet at the doses of 10, 20 or 30 mg/m2 by i.v. infusion. Plasma and urine concentrations of bromotetrandrine were determined by using a liquid chromatography–tandem mass spectrometric (LC/MS/MS) method. AUC was calculated by the trapezoidal rule extrapolation method. Cmax, Tmax, t1/2α, t1/2β, Cl and Vd were compiled from the plasma concentration–time data. Results: Bromotetrandrine was generally well tolerated at all doses. No serious or severe adverse events were found in the study. The pharmacokinetic parameters of BrTet after single i.v. infusion doses of BrTet 10, 20 and 30 mg/m2 were as follows: Tmax were 1·5 h in three groups, Cmax were 24·79, 39·59 and 64·31 μg/L, t1/2α were 0·37, 0·29 and 0·30 h, t1/2β were 62·88, 56·45 and 52·20 h. AUC0–194h were 345·83, 688·15 and 1096·28 μg h/L, Cl were 23·68, 25·69 and 25·66 L h/m2, Vd were 157·73,156·96 and 140·73 L/m2. In urine, the total eliminate rate of originate compound was 0·61 ± 0·19%. Conclusions: This study suggested that bromotetrandrine was well tolerated in healthy volunteers within the dose range evaluated. The pharmacokinetics parameters of bromotetrandrine indicated that the compound was rapidly distributed and accumulated in the tissues, and slowly cleared from plasma, which supported the use of BrTet for a once or twice dosing per chemotherapy cycle. 相似文献
28.
Gloria Peiró MD Encarna Adrover MD Jaime Guijarro MD Irene Ballester MD M. José Jimenez MD María Planelles MD Lluis Catasús BD 《The breast journal》2010,16(1):77-81
Abstract: Synchronous bilateral breast carcinoma (SBBC) and early onset are important characteristics of hereditary cases. The lifetime risk for breast carcinoma in Cowden syndrome (CS) is estimated to be 25–50%. We reported a 44‐year‐old woman presenting SBBC and characteristic mucocutaneous lesions of CS, confirmed by PTEN gene mutation analysis. Bilateral modified mastectomy and axillary dissection were performed. Histopathologic examination revealed a moderate‐differentiated invasive ductal carcinoma with mixed features of luminal A immunophenotype (Estrogen and/or Progesterone Receptors >50% and/or Ki67 < 30% of positive cells). The skin lesions showed the characteristic findings of tricholemmoma. Lack of PTEN expression was observed in all specimens. Sequencing analysis confirmed the presence of PTEN splice‐acceptor site mutation in intron 8 (c.1027‐2A>G), a germline mutation which had not been previously reported in CS. The patient received adjuvant chemotherapy and tamoxifen for 5 years. After 5 years of follow‐up, she persists recurrence‐free. SBBC with early onset suggests a hereditary predisposition. Thus, analysis of PTEN expression abnormality, easily assessed by immunohistochemistry, may be of clinical value to screen those patients with CS. 相似文献
29.
De Flora S; Camoirano A; Bagnasco M; Bennicelli C; Corbett GE; Kerger BD 《Carcinogenesis》1997,18(3):531-537
Estimates of the overall reducing capacity of hexavalent chromium(VI) in
some human body compartments were made by relating the specific reducing
activity of body fluids, cell populations or organs to their average
volume, number, or weight. Although these data do not have absolute
precision or universal applicability, they provide a rationale for
predicting and interpreting the health effects of chromium(VI). The
available evidence strongly indicates that chromium(VI) reduction in body
fluids and long-lived non-target cells is expected to greatly attenuate its
potential toxicity and genotoxicity, to imprint a threshold character to
the carcinogenesis process, and to restrict the possible targets of its
activity. For example, the chromium(VI) sequestering capacity of whole
blood (187-234 mg per individual) and the reducing capacity of red blood
cells (at least 93-128 mg) explain why this metal is not a systemic
toxicant, except at very high doses, and also explain its lack of
carcinogenicity at a distance from the portal of entry into the organism.
Reduction by fluids in the digestive tract, e.g. by saliva (0.7-2.1 mg/day)
and gastric juice (at least 84- 88 mg/day), and sequestration by intestinal
bacteria (11-24 mg eliminated daily with feces) account for the poor
intestinal absorption of chromium(VI). The chromium(VI) escaping reduction
in the digestive tract will be detoxified in the blood of the portal vein
system and then in the liver, having an overall reducing capacity of 3300
mg. These processes give reasons for the poor oral toxicity of chromium(VI)
and its lack of carcinogenicity when introduced by the oral route or
swallowed following reflux from the respiratory tract. In terminal airways
chromium(VI) is reduced in the epithelial lining fluid (0.9-1.8 mg) and in
pulmonary alveolar macrophages (136 mg). The peripheral lung parenchyma has
an overall reducing capacity of 260 mg chromium(VI), with a slightly higher
specific activity as compared to the bronchial tree. Therefore, even in the
respiratory tract, which is the only consistent target of chromium(VI)
carcinogenicity in humans (lung and sinonasal cavities), there are barriers
hampering its carcinogenicity. These hurdles could be only overwhelmed
under conditions of massive exposure by inhalation, as it occurred in
certain work environments prior to the implementation of suitable
industrial hygiene measures.
相似文献
30.